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 Myopia is increasing in prevalence world-wide [1], but
information remains fragmented about the regulation of ocu-
lar growth and the development of refractive errors. In animal
models, it has been shown that the alteration of retinal images
leads to altered gene expression and a change in eye growth
patterns. Myopia can be artificially induced by placing nega-
tive lenses in front of the eye or by reducing the retinal image
quality by a diffuser [2,3], whereas hyperopia can be gener-
ated by positive lens wear [4]. These eye growth responses
were shown in several animal models, including chicks [2],
tree shrews [5], marmosets [6] and rhesus monkeys [7]. In
mice, a shift toward myopia can be induced by form depriva-
tion [8-10]. During negative spectacle lens wear, axial eye
growth rates are accelerated until a sharp retinal image is
achieved. Depriving the retina of high contrast and high spa-
tial frequencies by diffusers also induces axial eye growth,
but a sharp retinal image cannot be restored in this case. A
local mechanism within the retina is involved in eye growth
regulation since neither accommodation nor contributions from
the brain are necessary [11].
Little is known about genes and proteins whose expres-
sion is susceptible to altered visual stimulation. Among the
known genes and substances are glucagon [12,13], retinoic
acid [14], vasointestinal peptide (Vip) [15-17], sonic hedge-
hog (Shh) [18,19], and the transcription factor Egr-1 [20,21].
The identification of novel retinal genes that are influenced
by altered visual conditions is important as they may lead to
new targets for a pharmacological therapy of myopia. In the
present study, DNA-microarrays, followed by semi-quantita-
tive real-time RT-PCR, were used to screen for differentially
regulated genes and subsequent validation.
METHODS
Animals:  Black wildtype C57BL/6 male mice were raised on
a 12 h: 12 h light-dark cycle with light onset at 8:00 a.m. The
mice were reared in the local animal facility and given free
access to water and food. For the GeneChip® experiments the
mice (3 per group) were studied at postnatal (P) days 30 and
32, while the mice used for the validation of the results by
semi-quantitative real-time RT-PCR (6 animals per group) were
studied at P29 to P36. The experimental treatment was in ac-
cordance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research and was approved by the
university commission for animal welfare (reference AK 3/
05).
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Purpose: The development of myopia is controlled by still largely unknown retinal signals. The aim of this study was to
investigate the changes in retinal mRNA expression after different periods of visual deprivation in mice, while controlling
for retinal illuminance.
Methods: Each group consisted of three male C57BL/6 mice. Treatment periods were 30 min, 4 h, and 6+6 h. High spatial
frequencies were filtered from the retinal image by frosted diffusers over one eye while the fellow eyes were covered by
clear neutral density (ND) filters that exhibited similar light attenuating properties (0.1 log units) as the diffusers. For the
final 30 min of the respective treatment period mice were individually placed in a clear Perspex cylinder that was posi-
tioned in the center of a rotating (60 degrees) large drum. The inside of the drum was covered with a 0.1 cyc/degree
vertical square wave grating. This visual environment was chosen to standardize illuminances and contrasts seen by the
mice. Labeled cRNA was prepared and hybridized to Affymetrix GeneChip® Mouse Genome 430 2.0 arrays. Alterations
in mRNA expression levels of candidate genes with potential biological relevance were confirmed by semi-quantitative
real-time reverse transcription polymerase chain reaction (RT-PCR).
Results: In all groups, Egr-1 mRNA expression was reduced in diffuser-treated eyes. Furthermore, the degradation of the
spatial frequency spectrum also changed the cFos mRNA level, with reduced expression after 4 h of diffuser treatment.
Other interesting candidates were Akt2, which was up-regulated after 30 min of deprivation and Mapk8ip3, a neuron
specific JNK binding and scaffolding protein that was temporally regulated in the diffuser-treated eyes only.
Conclusions: The microarray analysis demonstrated a pattern of differential transcriptional changes, even though differ-
ences in the retinal images were restricted to spatial features. The candidate genes may provide further insight into the
biochemical short-term changes following retinal image degradation in mice. Because deprivation of spatial vision leads
to increased eye growth and myopia in both animals and humans, it is believed some of the identified genes play a role in
myopia development.
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920Diffuser and neutral density filter design:  Diffusers were
made from transparencies that were sanded down with emery
paper to give a frosted appearance. Neutral density (ND) fil-
ters of 0.1 log unit light attenuation (Kodak Wratten Gelatin
Filter No. 96; Rochester, NY) were used to match image illu-
mination [21,22]. Velcro rings with an inner diameter of 6 mm
and a total diameter of 10 mm were fitted with the frosted
transparency or ND filter. The contralateral eyes served as
controls to minimize effects due to differences between indi-
vidual animals in factors such as hormone level and immuno-
logical state.
Treatment procedure:  Velcro rings were attached to the
periorbital fur the day before the experiments while animals
were under diethyl ether anesthesia. For anesthesia, animals
were put in a diethyl ether containing glass jar supplied with a
grid at the bottom. The glass jar was covered by a lid until the
animals were unconscious (which takes about 20-30 s). The
complementary Velcro rings carrying the diffusers and ND
filters were attached on the experimental day. Mice were kept
under cool white light of approximately 120 lux (Lumilux
30W/840; Osram, Munich, Germany) during the treatment
period and were sacrificed after a total of six hours in light
(Figure 1). At the end of the respective treatment period, each
mouse was separately placed on a stationary platform in the
center of the rotating drum with a diameter of 60 cm for 30
min. Illumination in the drum was about 400 lux. The stripe
pattern had a spatial frequency of 0.1 cycles per degree. The
angular velocity was about 60 degrees per second, which was
much higher than that used by Prusky et al. [23]. Previous
studies in our lab, using the drum, have shown that an angular
velocity of 50 to 60 deg/s was optimal for studying spatial
vision in C57BL/6 mice in our optomotor set-up [24].
The whole body optomotor grating acuity of C57BL/6
mice was recently measured in the same drum and was found
to be limited to approximately 0.3-0.4 cycles/degree. The stripe
contrast measured at 400 lux was approximately 90% [24].
Previous experiments have shown that the image contrast with
the diffusers used in the current study is reduced to about 60-
70% of the initial value [25]. The illumination before and dur-
ing the experiment was far below the illumination that was
previously used to induce retinal degeneration in mice [26].
To insure that gene expression changes were a result of the
treatment and not the hormone status, age, light, or time of
day, we only used male litter mates and sacrificed the mice
after they had been exposed to 6 h of light. This was usually
between 2 and 3 p.m. in the afternoon (Figure 1).
Tissue preparation and RNA isolation:  All mice were
sacrificed by an overdose of diethyl ether. Their eyes were
enucleated and immediately transferred to a petri dish con-
taining chilled Ringer’s solution until preparation. The eyes
were subsequently placed on a filter paper, perforated by a
canula and opened with scissors, cutting around the iris. The
lens was removed, and the retina was extracted, snap frozen
in liquid nitrogen, and stored at -70 °C. The preparation was
done using a stereo boom microscope (10X magnification)
and RPE cells were carefully removed. The total length of
time between death/enucleation and tissue freezing was about
5-10 min. Each retina was treated and analyzed as a separate
sample. The retinas were homogenized for 1 min with speed
increasing from 11,000 to 20,000 rpm (Diax 900 Homogenizer;
Heidolph, Kelheim, Germany). Total RNA was isolated with
a kit (RNeasy Mini Kit; Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. RNA quality and quantity
were determined by the Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA), which yielded RNA integrity
numbers (RIN) from 8.4 to 9.3.
Microarray analysis:  The GeneChip® mouse genome
430 2.0 Array from Affymetrix (Santa Clara, CA) allows the
comprehensive analysis of genome-wide expression on a single
array. We used 45,000 probe sets to analyze the expression
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Figure 1. Detailed representation of the treatment protocol.  A: shows
the protocol for the control animals. A-D: An arrow above each time
bar signals (1) the time when mice were brought into light, (2) when
each mouse was put into the rotating drum, and (3) when mice were
sacrificed. B-D: The arrows below the time bars mark the beginning
of each treatment: 30 min (B), 4 h (C), and 6+6 h (D) diffuser and
ND filter attachment. Three animals were treated per day, and were
brought into light as follows: the first mouse at 8.00 a.m., the second
at 8.30 a.m., and the third animal at 9.00 a.m. Accordingly, the entire
treatment schedule was shifted 30 min or 1 h later (to the right) for
the 2nd and 3rd animals, respectively.
921level of over 39,000 transcripts and variants from over 34,000
well-characterized mouse genes.
Microarray analysis was performed by the Affymetrix Re-
source Facility at the University of Tuebingen as follows. Tar-
get labeling for the expression analysis was performed for 1
µg total RNA per sample according to the manufacturer’s pro-
tocol (Affymetrix). The GeneChips® were automatically
stained and washed in a fluidics station as recommended by
the manufacturer. The scanning and the analysis were done
using the Affymetrix Microarray Suite Software (v. 5.0).
Affymetrix data analysis and statistics:  The relative abun-
dance of individual genes is based on the signal intensities of
the corresponding probe sets that were analyzed by ArrayAssist
4.0 (Stratagene, La Jolla, CA). The microarray data were not
Benjamini/Hochberg corrected since no significant differences
in gene expression were obtained when this procedure was
performed. Normalization and confirmation is covered in the
Discussion section. Data from the experiments involving 30
min, 4 h and 6+6 h treatments were individually normalized
using robust multi-array analysis with correction for GC con-
tent (gcRMA). The strategy of this normalization method is
the calculation of a background adjustment step that ignores
the mismatch (MM) intensities but incorporates sequence in-
formation from the probes (GC content) [27]. Afterwards the
data were analyzed group-wise by paired t-tests to find genes
that were differentially expressed in the diffuser- and filter-
treated eyes of the same animal. The p-value was below 0.05
and a minimum fold-change (FC) was 1.5. mRNA level
changes observed throughout the diffuser treatment were evalu-
ated by normalizing together raw data from all three microarray
experiments (30 min, 4 h, 6+6 h). One kind of background
adjustment was calculated for all the 18 arrays. The quality of
all microarray experiments was assessed by GAPDH 3'/5' and
Actin 3'/5' ratios as well as background, scalar factors and
present calls (Table 1) [28].
Network generation and pathway analysis:  The networks
and functional analyses were generated through the use of In-
genuity Pathways Analysis (Ingenuity® Systems).
A data set containing gene identifiers and corresponding
fold change values was uploaded into the application. Each
gene identifier was mapped to its corresponding gene object
in the Ingenuity Pathways Knowledge Base. These genes,
called focus genes, were overlaid onto a global molecular net-
work developed from information contained in the Ingenuity
Pathways Knowledge Base. Networks of these focus genes
were then algorithmically generated based on their connectiv-
ity.
Semi-quantitative real-time polymerase chain reaction:
All RNA samples used for semi-quantitative RT-PCR were
treated with RNase-free DNase I (Roche, Mannheim, Ger-
many). Gel electrophoresis was used to check quality of RNA.
Concentration and purity were determined by spectrophotom-
etry at 260 and 280 nm (average ratio 1.95±0.08). Of each
sample, 1 µg total RNA was reverse transcribed (M-MLV re-
verse transcriptase; Promega, Madison, WI) using a combina-
tion of 50 ng random hexamers and 500 ng oligo (dT)15 prim-
ers in a total volume of 20 µl.
Gene sequences chosen for validation were obtained from
the National Center for Biotechnology Information NCBI.
Primers (Table 2) were preferentially designed to bind within
the same coding region as the Affymetrix probes using a com-
mercial program (Prime; GeniusNet Husar; KYE Systems,
Heidelberg, Germany) and Primer Premier 5 (Premier Biosoft
International; Palo Alto, CA). They were ordered from a com-
mercial synthesis service (VBC Genomics, Vienna, Austria).
PCR was performed in a thermocycler (iCycler; Bio-Rad,
Hercules, CA) using a commercial fluorescence detection kit
(QuantiTect SYBR Green PCR kit; Qiagen). After an initial
heat activation (15 min at 95 °C) 40 cycles of 15 s at 94 °C, 30
s at 59 °C and 45 s at 72 °C were run. Cyclic fluorescence
measurements were taken at the end of the annealing phase.
The volume of a single reaction added up to 15 µl containing
2 ng template and a final primer concentration of 0.6 µM each.
All PCR products were verified by automated sequencing or
by restriction enzyme digestion (Usp36). Both the acidic ri-
bosomal protein (Arp) and β-actin were chosen as internal ref-
erence genes and used for subsequent analyses.
Semi-quantitative real-time reverse transcriptase poly-
merase chain reaction data analysis and statistics:  Measure-
ments were performed in triplicates and the CT (Threshold
Cycle) means were used for further data analyses by follow-
ing a procedure described in reference [29].
Briefly, the efficiencies (E) of the individual primer sets
during PCR were determined by dilution series and following
equation: E=10(-1/slope).
Statistical data analysis was performed after conversion
of the raw data into normalized expression (NE). Therefore,
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TABLE 1. QUALITY DATA OF THE GENECHIP® EXPERIMENTS
                    Array 30 min    Array 4 h     Array 6+6 h
-----------------   ------------   ------------   ------------
GAPDH 3'/5' ratio    0.74±0.03     0.89±0.01      0.79±0.02
Actin 3'/5' ratio    1.53±0.07     1.8±0.08       1.68±0.03
Background           51.13±6.59    80.52±6.94     81.68±18.5
Scalar factor        1.56±0.38     1.02±0.14      1.34±0.08
% present            56.69±1.34    54.45±1.19     52.4±1.44
The quality of each chip is evaluated and depends (among others) on
3'/5' ratios, the background and scalar factor. The percentage of present
calls is also an important indicator of quality. Shown are the mean
values of six arrays per treatment group with corresponding standard
deviation (SD). All values met the expected quality criteria.
TABLE 2. DESCRIPTION OF PRIMERS
Accession
  number        Gene      Sense primer (5'-3')    Antisense primer (5'-3')   Amplicon
----------   ----------   ---------------------   ------------------------   --------
M12481       beta-actin   GGCTATGCTCTCCCTCACG     CTTCTCTTTGATGTCACGCACG     144 bp
X15267       Arp          CCTCCTTCTTCCAGGCTTTG    GGCTCCCACCTTGTCTCC         104 bp
AK009241     Krt2-6b      GCTCACATCACGATTCACACA   GACAGGAAGGTTTATGAGGTTG     220 bp
NM_007434    Akt2         GAGGACAATGACTATGGGCG    TTCAGCAGTCCAGCCAGCA        191 bp
NM_033597    Myb          CCAGGAGAAGCATTATTTTGA   AACCATAGCAGCGAACACAT       254 bp
NM_013931    Mapk8ip3     ACTCCATCCTCACCAGTCCT    AGAGAGAGCAAAGGGTTGGA       123 bp
M20157       Egr-1        TAGCAGCAGCAGCACCAGC     CATAGGGTTGTTCGCTCGGC       101 bp
NM_010234    Fos          CCCTGTGAGCAGTCAGAGAA    GGTGTGTTTCACGAACAGGT       145 bp
XM_126772    Usp36        GCAGGACCTAATTCAGCACA    TGGGTGCTTGCTCTCTTCAT       139 bp
XM_355521    Zmym4        TTCAGTCAGTGGCAGTCCTCT   ACAACCAGAGCAAGAAACTCG      130 bp
NM_172803    Dock4        GCTTACCTGGAAGGCAGTG     CATCCACAACTGTTTGCTTT       192 bp
NM_010638    Klf9         GCCCACTGTGTGAGAAGAGA    TGTCAGTCTGTTTCCTGGGA       192 bp
NM_172406    Trak2        GCTGAGATTGAAGGGACCAT    AGTGTCATTGGCAACCTTGA       114 bp
NM_019635    Stk3         ATCCCTACAAACCCACCAC     GGCTCTCTGCTCAGGACTCT       105 bp
NM_010200    Fgf13        TGAACAGCGAGGGATACTTG    TTCACATGGTTGCCTTTCAT       184 bp
NM_013822    Jagged1      AACACCCGAACTGGACAAAT    GCCCACTGTCTGCTATACGA        95 bp
Shown are Genbank accession numbers, sequences and amplicon
lengths of the primers used.
922the CT means were transformed into relative quantities (RQ),
and corresponding normalization factors (NF) were deter-
mined.
For the RQs, all CT values obtained for a single gene were
considered (e.g. control, 30 min, 4 h, and 6+6 h group). The
sample showing the highest expression level (e.g. the lowest
CT) was set to 1 (reference sample, RS). All other RQs were
calculated by following formula:
Relative Quantity (Sample, S)=Efficiency(CT (RS)-CT (S)).
The normalization factor represents the geometric mean
(root) of the reference gene RQs:
NF=(RQ(β-actin)xRQ(Arp))1/2
The NE represents the ratio of the relative quantity of a
sample and its corresponding normalization factor: NE=RQ/NF
NE differences between diffuser-treated and ND filter-
covered fellow eyes were calculated and statistically analyzed
by un-paired Student’s t-tests against null.
RESULTS
GeneChip® results:  GeneChip® analysis was performed on
three animals per treatment group. mRNA expression levels
in the diffuser-covered eyes were calculated relative to those
in the ND filter-treated fellow eyes. After gcRMA normaliza-
tion, expression of 16 genes was found to be affected after 30
min, with 13 genes being up-regulated. The 4 h treatment re-
sulted in 27 differentially expressed genes, 23 of which were
down-regulated. After 6+6 h, the number of up- and down
regulated genes was balanced, with 10 genes being up-regu-
lated and 11 being down-regulated.
The genes were arranged in a list according to their major
function as determined by Ingenuity Pathways Analysis (Table
3).
To identify diffuser specific genes that were temporally
regulated, the raw data of all three microarray experiments
were normalized together and expression changes were deter-
mined by pair-wise comparisons. The p-value was set to 0.01
and a minimum fold change of 2.0 was established. The ex-
pression of 249 genes was significantly different after 6+6 h
versus 30 min of treatment, and that of 191 genes was signifi-
cantly different after 4 h versus 30 min of treatment but the
expression of only 49 genes was significantly different after
6+6 h versus 4 h of treatment. Six genes were chosen to con-
firm the temporal expression analysis: fibroblast growth fac-
tor 13 (Fgf13) mitogen-activated protein kinase 8 interacting
protein 3 (Mapk8ip3), trafficking protein, kinesin binding 2
(Trak2), Jagged 1 (Jag1), serine/threonine kinase 3 (Stk3), and
kruppel-like factor 9 (Klf9).
Semi-quantitative real-time reverse transcriptase poly-
merase chain reaction:  mRNA expression levels were evalu-
ated by real-time RT-PCR. Six animals were used in each
group. Genes chosen for validation met certain criteria. First,
the signal intensity in either group (diffuser or ND filter) ex-
ceeded 65, and second, the Affymetrix probe sets covered a
coding region (as determined by the University of California
Santa Cruz genome browser). The genes shown in Table 3
were identified after gcRMA normalization of the data set. A
previous analysis of the 30 min experiment using MAS5 nor-
malization resulted in a higher number of differentially regu-
lated genes and the confirmation of three genes (Akt2, Krt2-
6b, Myb) from that list. The issue of normalization is dealt
with in the Discussion section. Accordingly, eight potentially
interesting genes were selected for validation: early growth
response 1 (Egr-1), protein kinase B (Akt2), keratin complex
2, basic, gene 6b (Krt2-6b), myeloblastosis oncogene (Myb),
FBJ osteosarcoma oncogene (cFos), ubiquitin specific pepti-
dase 36 (Usp36), zinc finger, MYM-type 4 (Zmym4), and dedi-
cator of cytokinesis 4 (Dock4). The mRNA expression levels
of these genes were measured in diffuser- and ND filter-treated
eyes by RT-PCR (Figure 2).
The differential expression of most genes could be confirmed
by semi-quantitative real-time RT-PCR. However, the differ-
ential expression of Dock4 (p=0.07) and Myb (p=0.09) just
missed significance, and the differential expression of Usp36
and Zmym4 also could not be confirmed. The correlation (Table
4) between the results obtained by the GeneChip® experi-
ment and by real-time PCR was good (R=0.86; p<0.01).
Expression of Egr-1 and cFos mRNA as a function of time:
The impact of diffuser and ND filter treatment on Egr-1
and cFos mRNA expression was analyzed over time and also
compared to a group of untreated control animals (Figure 3).
The Egr-1 mRNA level in the eyes of treated animals was
remarkably reduced when compared to that in the control
group. Real-time RT-PCR data were analyzed statistically by
ANOVA followed by Dunnett’s test (p<0.001). After 30 min,
the average Egr-1 mRNA level dropped to about 26% of the
control group level. After 4 h of treatment the mean mRNA
expression level was about 14% of the initial value, and at the
end of the 6+6 h treatment, mean mRNA expression level was
approximately 10% of the baseline level. The reduction of
image intensity therefore had a higher impact on Egr-1 ex-
pression level than did the changes in image contrast and spa-
tial frequency content that were induced by diffuser wear.
Nevertheless, the mRNA expression differences (Figure 2)
between the diffuser- and ND filter-treated eyes persisted for
6+6 h.
cFos mRNA expression was also found to be decreased
by the treatment in comparison to the control group. The real-
time RT-PCR data were analyzed statistically by ANOVA fol-
lowed by Dunnett’s test (C versus ND Filter 24 h: p<0.05; C
versus all other groups: p<0.001). It was found that after 30
min, the average cFos mRNA level dropped to 35% of the
baseline level but increased subsequently. After 4 h the mean
mRNA expression level was approximately 44% of the initial
value, and after 6+6 h the mean mRNA expression level in-
creased by 17% reaching 61% of the control group level. As
in the case of Egr-1, the reduction of image intensity had a
high impact on cFos expression, but differences between dif-
fuser- and ND filter-treated eyes were still apparent after 6+6
h (Figure 2).
Baseline expression levels of Akt2, Krt2-6b, Myb,
Zmym4, Usp36, and Dock4: Baseline expression level of the
genes chosen for validation was evaluated by measuring tar-
get gene expression in an untreated control group. The control
group was sacrificed after 6 h of light exposure to circumvent
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TABLE 3. LIST OF GENES OBTAINED BY PAIRED ANALYSIS AND GCRMA NORMALIZATION
Treatment 30 min
 Gene ID         FC                                Gene title
------------   -----   ----------------------------------------------------------------------
Transcription regulator (3)
13653          -1.65   early growth response 1 (Egr-1)
22141          1.51    tubby homolog (mouse; Tub)
17260          1.63    MADS box transcription enhancer factor 2, polypeptide C (Mef2c)
Transporter (3)
73836          1.53    solute carrier family 35, member B2 (Slc35b2)
18824          2.00    proteolipid protein 2 (colonic epithelium-enriched; Plp2)
224022         2.26    solute carrier family 7, member 4 (Slc7a4)
Transmembrane receptor (1)
22288          1.59    utrophin (homologous to dystrophin; Utrn)
Peptidase (1)
69617          -1.55   pitrilysin metallopeptidase 1 (Pitrm1)
Enzyme (3)
545195         1.50    cytochrome P450, family 4, subfamily f, polypeptide 16 (Cyp4f16)
69719          1.70    carbamoyl-phosphate synthetase 2, aspartate transcarbamylase,
                       and dihydroorotase (Cad)
54616          1.72    exostoses (multiple)-like 3 (Extl3)
Other (4)
26936          -1.58   myosin phosphatase-Rho interacting protein (m-Rip)
57908          1.52    zinc finger protein 318 (Zfp318)
320165         1.52    transforming, acidic coiled-coil containing protein 1 (Tacc1)
320295         1.58    RIKEN cDNA C920006O11 gene (C920006O11Rik)
Unknown (1)
1427797_s_at   1.62
Treatment 4 h
Gene ID          FC                               Gene title
------------   -----   ----------------------------------------------------------------------
Transcription regulator (5)
13653          -2.20   early growth response 1 (Egr1)
14281          -2.05   FBJ murine osteosarcoma viral oncogene homolog (cFos)
225872         -1.91   neuronal PAS domain protein 4 (Npas4)
21418          -1.52   transcription factor AP-2 alpha (Tcfap2a)
21677           1.56   TEA domain family member 2 (Tead2)
Transporter (1)
317717         -1.59   SEC22 vesicle trafficking protein homolog A
                       (S. cerevisiae; Sec22l2)
Peptidase (1)
72344          1.61    ubiquitin specific peptidase 36 (Usp36)
Kinase (1)
56637          -1.52   glycogen synthase kinase 3 beta (Gsk3b)
Enzyme (2)
12662          -1.74   choroideremia (Rab escort protein 1; Chm)
78797          -1.52    NADPH dependent diflavin oxidoreductase 1 (Ndor1)
924©2007 Molecular Vision Molecular Vision 2007; 13:920-32 <http://www.molvis.org/molvis/v13/a98/>
Treatment 4 h, contunued
Gene ID          FC                               Gene title
------------   -----   ----------------------------------------------------------------------
Other (14)
19707          -2.27   RALBP1 associated Eps domain containing 1 (Reps1)
68607          -2.01   serine hydrolase-like 2 (Serhl)
67785          -1.95   zinc finger, MYM-type 4 (Zmym4)
22289          -1.71   ubiquitously transcribed tetratricopeptide repeat,
                       X chromosome (Utx)
104910         -1.63   chromosome 14 open reading frame 68 (C14ORF68)
67974          -1.56   chromosome 10 open reading frame 9 (C10ORF9)
15982          -1.53   interferon-related developmental regulator 1 (Ifrd1)
70828          -1.53   RIKEN cDNA 4633401B06 gene (4633401B06Rik)
109200         -1.51   RIKEN cDNA A430102J17 gene (A430102J17Rik)
77656          -1.51   RIKEN cDNA C430045I18 gene (C430045I18Rik)
216971         -1.51   chromosome 17 open reading frame 63 (C17ORF63)
320003         -1.50   RIKEN cDNA C430014K11 gene (C430014K11Rik)
78893           1.53   CCR4-NOT transcription complex, subunit 10 (Cnot10)
52710           1.54   G protein-coupled receptor 172A (Gpr172b)
Unknown (3)
1443057_at     -2.41
1446932_at     -1.83
1444274_at     -1.60
Treatment 6+6 h
  Gene ID        FC                                 Gene title
------------   -----   ----------------------------------------------------------------------
Transcription regulator (2)
13653          -1.77   early growth response 1 (Egr1)
109115         -1.67   suppressor of Ty 3 homolog (S. cerevisiae; Supt3h)
Transporter (1)
224022         -1.55   solute carrier family 7, member 4 (Slc7a4)
Enzyme (5)
74335          -1.90   X-ray repair complementing defective repair inChinese hamster
                       cells 3 (Xrcc3)
50505          -1.69   excision repair cross-complementing rodent repair deficiency,
                       complementation group 4 (Ercc4)
19361          -1.68   RAD51 homolog (RecA homolog, E. coli; S. cerevisiae; Rad51)
13804          -1.68   endonuclease G (Endog)
242202          1.64   phosphodiesterase 5A, cGMP-specific (Pde5a)
Other (12)
627191         -1.87   transmembrane protein 90a (Tmem90a)
237781         -1.52   Smith-Magenis syndrome chromosome region, candidate 7 (Smcr7)
76073          -1.51   polycomb group ring finger 5 (Pcgf5)
19650          -1.51   retinoblastoma-like 1 (p107; Rbl1)
210766         1.55    BRCA1/BRCA2-containing complex, subunit 3 (Brcc2)
238130         1.56    dedicator of cytokinesis 4 (Dock4)
20324          1.58    serum deprivation response (phosphatidylserine binding protein; Sdpr)
320191         1.61    hook homolog 3 (Drosophila; Hook3)
67693          1.61    Huntingtin interacting protein K (Hypk)
19359          1.65    RAD23 homolog B (S. cerevisiae; Rad23b)
211550         1.69    TRAF-interacting protein with a forkhead-associated domain (Tifa)
73126          1.72    RIKEN cDNA 3110038A09 gene (3110038A09Rik)
Unknown (1)
1440123_at     1.61
“Entrez gene” accession numbers or Affymetrix ID (Gene ID), fold changes (FC) and names of the genes that were differentially expressed in
the diffuser covered eyes relative to the ND filter treated control eyes are displayed. A p<0.05 was considered significant. Genes chosen for
validation are colored in red.
925diurnal influences on mRNA levels (Figure 1A). Real-time
RT-PCR data (Figure 4) were analyzed statistically by ANOVA
followed by Tukey-Kramer HSD tests.
The mRNA expression of Akt2 and Dock4 increased in
both diffuser- and ND filter-treated eyes, however, the increase
was more pronounced in the diffuser-treated eyes. In contrast,
Krt2-6b expression was substantially high in untreated ani-
mals, while it was lower in the treated animals. Myb expres-
sion was hardly detectable in the control group and therefore
seems to be induced by the treatment conditions. Usp36 mRNA
level seemed to be higher in diffuser- and ND filter-treated
eyes, although not statistically significant. Zmym4 mRNA ex-
pression was not influenced by either treatment condition.
Semi-quantitative real-time reverse transcriptase poly-
merase chain reaction: Six potentially interesting genes were
selected to validate the diffuser specific expression changes
over time: Fgf13, Mapk8ip3, Trak2, Jag1, Stk3, and Klf9
mRNA. Their levels were measured in diffuser-treated eyes
only. Baseline expression levels were determined in untreated
control animals that spent 6 h in light, including 30 min in the
rotating drum. The statistical analysis was done by ANOVA
followed by pair-wise Tukey-Kramer HSD post hoc tests (Fig-
ure 5).
The microarray results were fully confirmed by real-time
RT-PCR for Fgf13 (Figure 5A) and Mapk8ip3 (Figure 5B), in
part for Stk3 (Figure 5E), and Trak2 (Figure 5C), but not for
Klf9 (Figure 5F), and Jag1 (Figure 5D). Possible reasons for
this are addressed in the Discussion section. For the purpose
of clarity, not all significant changes are shown in Figure 5B
but were as follows: the Mapk8ip3 mRNA level was signifi-
cantly decreased in the treatment groups when compared to
the control group (control versus 30 min: p<0.01; control ver-
sus 4 h and 6+6 h: p<0.001).
Network analysis:  Molecular networks comprising the
differentially regulated genes were generated through the use
of Ingenuity Pathways Analysis. The relatively low number
of differentially expressed genes could not be consigned to a
specific pathway. After 30 min and 4 h of deprivation, most of
the genes that changed were involved in cellular development,
whereas after 1 day of treatment, they were mostly involved
in DNA replication, recombination, nucleic acid metabolism,
and small molecule biochemistry.
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Figure 2. Analysis of GeneChip® results by real-time reverse tran-
scriptase polymerase chain reaction.  Delta values were calculated
between the normalized expression values of the diffuser- and neu-
tral density (ND) filter-treated eyes and are plotted on the ordinate.
Six mice were used for each experiment. Results were given as fol-
lows for each treatment group: (A) 30 min treatment group, (B) pre-
sents 4 h group and (C) 6+6 h group. Single asterisk represents p<0.05
*; while double asterisk indicates p<0.01 **. Error bars denote stan-
dard errors of the mean.
TABLE 4. CORRELATIONS BETWEEN RESULTS OBTAINED BY
MICROARRAY AND REAL-TIME POLYMERASE CHAIN REACTION ANALYSIS
 Gene        Time     Microarray    PCR
-------   ---------   ----------   -----
Egr-1     30 min        -1.65      -1.49
Akt2      30 min        1.73       1.34
Krt2-6b   30 min        14.1       3.08
Myb       30 min        -2.22      -1.64
Egr-1     4 h           -2.2       -1.97
Fos       4 h           -2.05      -2.1
Usp36     4 h           1.61       -1.13
Zmym4     4 h           -1.95      -1.07
Egr-1     6+6 h         -1.77      -2.05
Dock4     6+6 h          1.56      1.37
The changes that were obtained by the two methods are expressed as
the ratio of the expression level in the diffuser-treated eyes to the
expression level in the ND filter-treated eyes.
926DISCUSSION
 Placing diffusers over the eyes can artificially induce
myopia in animal model. The identification of retinal genes
and proteins that are induced or repressed by such conditions
can provide new candidates for pharmacological intervention
of myopia also in humans. The present study demonstrated
that short as well as longer periods of retinal image degrada-
tion cause significant changes in the expression level of some
genes.
Egr-1 mRNA expression: The influence of form depriva-
tion on Egr-1 mRNA expression [21] could be confirmed and
strengthened in the present study, since Egr-1 expression was
decreased in the diffuser-treated eyes at all time points even
though the intensity of the retinal images was matched in both
eyes. Moreover, Egr-1 expression in the retina was strongly
regulated by light. In other species it was shown that in a sub-
set of cells, Egr-1 was not regulated by the light intensity but
instead regulated by the sign of defocus (i.e. the glucagonergic
amacrine cells in the chicken retina and the GAD65 cells in
the macaque retina). In these cells, Egr-1 might induce growth
signals independently from the lighting situation. We suggest
that there exists a focus-sensitive subpopulation of Egr-1 ex-
pressing cells in the murine retina as well.
The early growth response protein 1 (Egr-1) [30] was first
identified as an immediate early gene responsive to growth
factors and various differentiation signals and later confirmed
as a transcriptional regulatory protein. It is induced in the ab-
sence of de novo protein synthesis by mitogens, developmen-
tal or differentiation cues, tissue or radiation injury or signals
that cause neuronal excitation [31]. The zinc-finger protein
Egr-1 is located in the nucleus [32-34] and has numerous tar-
get genes [35], among which are PDGF-A [36] and PDGF-B
[37], bFGF [38] and TGF-β1 [37,39]. A potential connection
between Egr-1 and myopia was first described in the chick,
where it was found that the expression of ZENK correlates
with the sign of defocus imposed by lenses in a subset of ama-
crine cells (AC), specifically the glucagon AC [20]. In the
macaque retina it was shown that focus-sensitive immunore-
activity for Egr-1 is induced in a subpopulation of GABAergic
amacrine cells (GAD65-immunoreactive cells) [22].
cFos mRNA expression: The decreased expression of cFos
mRNA as a result of reduced image quality was determined
by microarray analysis after 4 h of treatment. Furthermore,
the analysis by real-time RT-PCR also revealed a down-regu-
lation of cFos mRNA in the diffuser-treated eyes after 30 min
and even after 6+6 h. The level of cFos mRNA, in contrast to
that of Egr-1 mRNA, increased slightly over time in both dif-
fuser and in ND filter-treated eyes, implying that the two genes
are independently regulated when the image contrast is re-
duced by diffusers. The independent regulation of those two
immediate early genes has been previously shown in the chick
retina [20].
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Figure 3. Expression of Egr-1 and cFos in control animals and as a
function of time in treated animals.  The mRNA expression of Egr-1
(A) and cFos (B) in diffuser- and neutral density (ND) filter-treated
eyes is displayed as a function of time. Normalized expression val-
ues were plotted on the ordinate. Error bars denote standard errors of
the mean (SEM). Statistical results represent the ANOVA followed
by Dunnett’s test (comparisons with a control). Single asterisk indi-
cates p<0.05 *; while triple asterisk denotes p<0.001 ***. Three con-
trol animals and six treated animals were used for each experiment.
Figure 4. Retinal mRNA expression levels in untreated (control) and
treated (diffuser/filter) animals.  Normalized expression values were
plotted on the ordinate. Error bars denote standard errors of the mean
(SEM). Statistical results represent the ANOVA followed by Tukey-
Kramer test. A single asterisk indicates p<0.05 *, while a double
asterisk denotes p<0.01 **, and a triple asterisk marks p<0.001 ***.
Three control animals and six treated animals were used in these
experiments.
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Figure 5. mRNA expression levels in the diffuser-treated eyes as a function of time.  Normalized expression values for Fgf13 (A), Mapk8ip3
(B), Trak2 (C), Jag1 (D), Stk3 (E), and Klf9 (F) were plotted on the ordinate. Each black dot represents the approximate expression level
changes as determined by the GeneChip® experiment. Error bars denote standard errors of the mean (SEM). Statistical results represent the
ANOVA followed by Tukey-Kramer test. A single asterisk indicates p<0.05 *, a double asterisk equals p<0.01 **, and a triple asterisk
representsp<0.001 ***. Three control animals and six treated animals were used for each experiment.
928cFos is an immediate early gene that belongs to the acti-
vator protein (AP)-1 transcription factor family [40-42]. In
the retina, Fos-like protein expression has been found to be
induced by light in amacrine cells and ganglion cells of dark-
adapted rabbits [43]. The activation of cFos in response to
light onset, and its circadian regulation, have been described
in many studies [44-47]. The role of cFos in myopia research
has been previously investigated in the chick retina, where it
was found that switching from diffuse blur to focused vision
induced cFos protein expression in an amacrine cell subpopu-
lation [48]. Thus changes in cFos gene expression might indi-
cate the activation of retinal interneurons or circuits that me-
diate the growth responses to well-focused images. Further-
more, the transcriptional activity of c-Jun and cFos can be
inhibited by retinoic acid receptors in response to their ligands
[49]. Conversely, AP-1 represses the transactivation of retin-
oid receptors [50,51]. Retinoic acid has been previously im-
plicated in the regulation of eye growth. The synthesis of
retinoic acid is regulated in a focus-dependent manner in the
choroid and the retina [52-54] and the expression of retinal
retinoic acid receptors was found to be increased under form-
deprivation conditions [55].
Akt2 (also called protein kinase B β, PKBβ) is a serine/
threonine protein kinase and a downstream effector of the
phosphatidylinositol 3-kinase (PI3K). Many physiological
effectors and pharmaceuticals, including insulin, insulin-like
growth factor, vascular endothelial growth factor, nerve growth
factor, carbachol, forskolin and vanadate, are capable of in-
ducing Akt kinase activity, primarily in a PI3K-dependent
manner [56]. However, it has been found that Akt is also acti-
vated independently of the PI3K by heat shock and
hyperosmolarity [57] as well as oxidative stress and chemical
stressors [58]. Akt was first implicated in signal transduction
by the demonstration that its kinase activity is induced by
growth factors such as platelet derived growth factor (PDGF)
and basic fibroblast growth factor (bFGF) [59,60]. Further-
more, it has been shown that Akt2 detaches from the inner
surface of the plasma membrane, where it is initially activated,
and translocates to the nucleus within 30 min of its activation
by growth factors [61]. In the nucleus, Akt isoforms have been
hypothesized to phosphorylate and modulate the activity of
transcription factors [56].
In mammals, Akt2 is expressed in most tissues and or-
gans including the retina, but especially in insulin-responsive
tissues [62,63]. Previous experiments of our group have shown
that insulin might act as a growth stimulator (unpublished data
by MF obtained from studies in the chick). Akt2 therefore may
be a new and interesting candidate for involvement in signal
transduction during myopia development.
Krt2-6b, Myb, and Dock4 expression: Fewer details are
known about the other genes that were found to be regulated
by deprivation: Krt2-6b (also called mK6b), the expression of
which was reduced after 30 min of diffuser treatment and even
more after neutral density filter treatment compared to un-
treated control eyes, encodes an intermediate filament featur-
ing a complex expression pattern. Krt2-6b is constitutively
expressed in a variety of internal stratified epithelia but the
expression can also be induced by injury and other acute chal-
lenges. mRNA is induced in the epidermis as early as 1 h fol-
lowing acute injury or topical application of phorbol esters
[64] or retinoic acid [65].
Myb (also called c-myb) expression was induced by dif-
fuser treatment and to an even higher extent by filter wear.
Myb is a myeloblastosis oncogene acting as a transcriptional
transactivator. Gene knockout experiments have shown that
genes of the Myb family play an essential role in develop-
ment [66]. Myb is expressed in ganglion, amacrine, horizon-
tal, and photoreceptor cells of adult mice, suggesting that it
might play a role in the physiology of retinal cells [67]. Myb
family target genes accomplish diverse functions in cell death,
cell adhesion, transcription and signal transduction.
Dock4 is a potent rac activator and an unconventional gua-
nine exchange factor for the Rho family of guanosine triphos-
phatases (Rho GEF GTPases), as a protein interacting with
harmonin, which is expressed in the inner and outer photore-
ceptor segments. Mutations in the actin bundling and PDZ
domain-containing protein harmonin are the causes of Usher
syndrome type 1C (USH1C), a syndrome of congenital deaf-
ness and progressive blindness [68].
Data normalization and statistical analysis of microarray
experiments:  Initially, the data of the 30 min experiment were
normalized using MAS5 (Microarray Suite 5.0), resulting in
169 differentially expressed genes (FC 1.5, p <0.01). Since
gcRMA normalization is currently recommended as the
method of choice by some authors [69], it was subsequently
applied to normalize the data of all experiments. Based on
this method, the obtained list contained only 16 genes. The
same was true for the 4 h and the 6+6 h experiments, where
173 and 164 differentially expressed genes were obtained when
MAS5 normalization was conducted, respectively. In a com-
parison of the MAS5 and gcRMA generated gene lists, only
cFos was found in both lists obtained for the 4 h experiment.
The other lists showed no overlap. This result clearly shows
that differences in the normalization method may have a dra-
matic influence on the outcome of microarray studies. How-
ever, no clear consensus exists as to which method is best un-
der a given set of circumstances [70]. A major difference be-
tween both normalization strategies is the correction for hy-
bridization to the mismatch (MM) probes for that particular
probe set as applied by MAS5 while gcRMA alternatively
calculates a background adjustment step that ignores the MM
intensities but incorporates sequence information from the
probes (GC content) [27].
Although it is obvious that the mode of normalization has
a considerable effect, the genes chosen from either list could
be confirmed in our case. Both approaches give therefore only
an incomplete, and perhaps partially flawed, picture.
It is also important to mention that even though the data
were not Benjamini/Hochberg corrected we were neverthe-
less able to confirm some of the differentially expressed genes
which were detected with less rigorous statistical testing. This
may suggest that a more pragmatic approach with less statisti-
cal rigor, but more repeated experiments, may represent a more
successful screening procedure.
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929The low number of differentially expressed genes might
mirror the fact that a limited number of quite specific changes
are expected in the retina during eye growth regulation. It
seems likely that the circuits that control eye growth have to
operate without compromising other retinal and ocular func-
tions, and that they are therefore localized to a sub-set of reti-
nal neurons.
Another reason for the low number of differentially ex-
pressed transcripts might also be that, unless a gene is ex-
pressed by just one type of cell, the data could conceal oppo-
site changes in expression in two or more cell types. Thus, for
example, “zero” difference could result from equal and oppo-
site changes in two cell types, and “increase” could result from
a larger increase in one cell type and a lesser decrease in an-
other type of cell.
Confirmation of microarray results:  Most of the changes
in gene expression detected by microarray and chosen for fur-
ther study were validated by RT-PCR. Nevertheless, some of
the microarray results, particularly the changes in expression
over time, were not confirmed. One reason might be that com-
paring the independent microarray experiments is more com-
plicated, since the preparations and all following procedures
of the different treatment periods were done with some time
delay. As previously discussed, normalization is a critical point
in microarray analysis, and normalizing the data of all 18
GeneChips® together may carry a risk of potential bias.
Another reason for the difficulties of validation could be
that some of the differences between expression in treated and
control eyes were minute and therefore difficult to confirm.
Time kinetics:  The identification of genes that are tem-
porally regulated by diffuser treatment would be of interest,
even though the confirmation of the results proved to be diffi-
cult. We think that the results obtained by real-time RT-PCR
are more reliable, considering the issues of normalization.
Unfortunately, there is little information about the genes
for which the time kinetics was examined: Longer treatment
periods (4 h, 6+6 h diffuser wear) increased Fgf13 mRNA
levels in our study. Its exact function is unknown but Fgf13
was also found to be up-regulated after light-induced retinal
damage [71].
Mapk8ip3 (also called Jip3 or JSAP1) mRNA levels were
strongly reduced in diffuser-treated eyes. Mapk8ip3 is a scaf-
fold protein and brings together consecutive members of the
c-Jun NH2-terminal kinase (JNK) signaling cascade [72]. It is
expressed exclusively in neurons and binds preferentially to
JNK3 and also to the MAPK kinase 7 [73].
Conclusion and outlook:  The microarray technique is a
powerful technology, offering the possibility to assay thou-
sands of genes in one reaction. Each method has its limita-
tion, and it will therefore never be possible to identify all gene
expression changes using only one method. There is evidence
from the literature that the extent of changes in retinal mRNA
levels during deprivation is sometimes only small and there-
fore in the range of the detection limit of the used methods
(for example Northern blots or real-time PCR). We set the
cut-off level for the discovery of differentially expressed genes
to more than 1.5 fold, which also included the risk of missing
some differentially expressed genes.
It is important to keep in mind that changes in the mRNA
level are not always translated into changes in protein content
and that post-translational modifications of proteins may also
be involved in eye growth regulation. Therefore, a histologi-
cal study of Akt2 and cFos protein expression in the mouse
retina following deprivation seems to be interesting and is
planned. It might also be interesting to investigate the expres-
sion of the Jun proteins (c-Jun, JunB and JunD) since they
dimerize with Fos family members (cFos, FosB, Fra-1, and
Fra-2) to form transcriptionally active complexes [74]. More-
over, the mRNA expression pattern of some candidate genes
identified in this screening could also be studied in the chick,
which is easier to handle and responds more reliably with de-
velopment of myopia when diffusers are attached.
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